Daniel Wu
Hematology & Oncology · Seattle, WANPI 1447340195
Payments from drug & device makers
$449,385in general payments, 2019–2025
Across 43 payments — averaging $10,451 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$233K
- Daiichi Sankyo Inc.$148K
- AstraZeneca$28K
- Eli Lilly$28K
- Genentech, Inc.$13K
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 12 | $233,028 |
| Daiichi Sankyo Inc. | 12 | $148,021 |
| AstraZeneca | 5 | $28,039 |
| Eli Lilly | 3 | $27,687 |
| Genentech, Inc. | 11 | $12,610 |
How this compares
$449,385 in reported general payments places this provider in the 75th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
- Lawrence FongSeattle$9.7M
- Cameron TurtleSeattle$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.